Published in Women's Health Weekly, January 11th, 1999
Writing in the January 6, 1999, issue of the Journal of the National Cancer Institute, the researchers reported that overproduction of a certain growth factor, called TGF-beta, contributes to tamoxifen resistance. They also demonstrated that the immune system's natural killer activity is important for tamoxifen's anti-cancer effects.
Ultimately, both findings might be exploited to keep tumors...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly